Erwan Bezard - Publications

Affiliations: 
Université de Bordeaux, Talence, Nouvelle-Aquitaine, France 
Area:
neurodegenerative disorders
Website:
http://www.inb.u-bordeaux2.fr/dev/FR/equipe.php?equipe=Physiopathologie%20des%20syndromes%20parkinsoniens

291 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Teil M, Doudnikoff E, Thiolat ML, Bohic S, Bezard E, Dehay B. The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration. Molecular Neurobiology. PMID 35915387 DOI: 10.1007/s12035-022-02974-5  0.674
2022 Arotcarena ML, Soria FN, Cunha A, Doudnikoff E, Prévot G, Daniel J, Blanchard-Desce M, Barthélémy P, Bezard E, Crauste-Manciet S, Dehay B. Acidic nanoparticles protect against α-synuclein-induced neurodegeneration through the restoration of lysosomal function. Aging Cell. 21: e13584. PMID 35318803 DOI: 10.1111/acel.13584  0.678
2022 Teil M, Dovero S, Bourdenx M, Arotcarena ML, Camus S, Porras G, Thiolat ML, Trigo-Damas I, Perier C, Estrada C, Garcia-Carrillo N, Morari M, Meissner WG, Herrero MT, Vila M, ... ... Bezard E, et al. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain : a Journal of Neurology. PMID 35285474 DOI: 10.1093/brain/awab374  0.832
2022 Bezard E, Dehay B. [Aggregation and spread of synuclein in Parkinson's disease]. Medecine Sciences : M/S. 38: 45-51. PMID 35060886 DOI: 10.1051/medsci/2021241  0.667
2022 Laferrière F, Claverol S, Bezard E, De Giorgi F, Ichas F. Similar neuronal imprint and no cross-seeded fibrils in α-synuclein aggregates from MSA and Parkinson's disease. Npj Parkinson's Disease. 8: 10. PMID 35027576 DOI: 10.1038/s41531-021-00264-w  0.309
2022 Novello S, Mercatelli D, Albanese F, Domenicale C, Brugnoli A, D'Aversa E, Vantaggiato S, Dovero S, Murtaj V, Presotto L, Borgatti M, Shimshek DR, Bezard E, Moresco RM, Belloli S, et al. In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity. Neurobiology of Disease. 162: 105579. PMID 34871735 DOI: 10.1016/j.nbd.2021.105579  0.798
2021 Blesa J, Foffani G, Dehay B, Bezard E, Obeso JA. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nature Reviews. Neuroscience. PMID 34907352 DOI: 10.1038/s41583-021-00542-9  0.671
2021 Arotcarena ML, Dovero S, Biendon N, Dutheil N, Planche V, Bezard E, Dehay B. Pilot Study Assessing the Impact of Intrathecal Administration of Variants AAV-PHP.B and AAV-PHP.eB on Brain Transduction in Adult Rhesus Macaques. Frontiers in Bioengineering and Biotechnology. 9: 762209. PMID 34869273 DOI: 10.3389/fbioe.2021.762209  0.761
2021 Malave L, Zuelke DR, Uribe-Cano S, Starikov L, Rebholz H, Friedman E, Qin C, Li Q, Bezard E, Kottmann AH. Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia. Communications Biology. 4: 1071. PMID 34552196 DOI: 10.1038/s42003-021-02567-3  0.428
2021 Bassil F, Delamarre A, Canron MH, Dutheil N, Vital A, Négrier-Leibreich ML, Bezard E, Fernagut PO, Meissner WG. Impaired brain insulin signalling in Parkinson's disease. Neuropathology and Applied Neurobiology. PMID 34405431 DOI: 10.1111/nan.12760  0.636
2021 Darricau M, Canron MH, Bosc M, Arotçarena ML, Quang ML, Dehay B, Bezard E, Planche V. Lack of limbic-predominant age-related TDP-43 encephalopathy (LATE) neuropathological changes in aged macaques with memory impairment. Neurobiology of Aging. 107: 53-56. PMID 34384992 DOI: 10.1016/j.neurobiolaging.2021.07.009  0.559
2021 Sun X, Yu X, Zhang L, Zhao W, Wang M, Zhang Y, Li X, Gao R, Breger LS, Dovero S, Porras G, Fernagut PO, Dehay B, Bezard E, Qin C. Comparison of the expression and toxicity of AAV2/9 carrying the human A53T α-synuclein gene in presence or absence of WPRE. Heliyon. 7: e06302. PMID 33665452 DOI: 10.1016/j.heliyon.2021.e06302  0.804
2021 Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell LR, Schembri LS, Svenningsson P, Fernagut PO, Crossman AR, Bezard E, Andrén PE. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Science Advances. 7. PMID 33523980 DOI: 10.1126/sciadv.abe5948  0.799
2021 Feyder M, Plewnia C, Lieberman OJ, Spigolon G, Piccin A, Urbina L, Dehay B, Li Q, Nilsson P, Altun M, Santini E, Sulzer D, Bezard E, Borgkvist A, Fisone G. Involvement of Autophagy in Levodopa-Induced Dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33460487 DOI: 10.1002/mds.28480  0.661
2021 Yu X, Persillet M, Zhang L, Zhang Y, Xiuping S, Li X, Ran G, Breger LS, Dovero S, Porras G, Dehay B, Bezard E, Qin C. Evaluation of blood flow as a route for propagation in experimental synucleinopathy. Neurobiology of Disease. 105255. PMID 33421564 DOI: 10.1016/j.nbd.2021.105255  0.787
2020 Deffains M, Canron MH, Teil M, Li Q, Dehay B, Bezard E, Fernagut PO. L-DOPA regulates α-synuclein accumulation in experimental parkinsonism. Neuropathology and Applied Neurobiology. PMID 33275784 DOI: 10.1111/nan.12678  0.786
2020 Marmion DJ, Rutkowski AA, Chatterjee D, Hiller BM, Werner MH, Bezard E, Kirik D, McCown T, Gray SJ, Kordower JH. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease. 105184. PMID 33221532 DOI: 10.1016/j.nbd.2020.105184  0.324
2020 Outeiro TF, Heutink P, Bezard E, Cenci AM. From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33200446 DOI: 10.1002/mds.28387  0.348
2020 Bengoa-Vergniory N, Faggiani E, Ramos-Gonzalez P, Kirkiz E, Connor-Robson N, Brown LV, Siddique I, Li Z, Vingill S, Cioroch M, Cavaliere F, Threlfell S, Roberts B, Schrader T, Klärner FG, ... ... Bezard E, et al. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. Nature Communications. 11: 4885. PMID 32985503 DOI: 10.1038/s41467-020-18689-x  0.671
2020 Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, Andren PE, Crossman AR. µ opioid receptor agonism for L-DOPA-induced dyskinesia in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 32690616 DOI: 10.1523/JNEUROSCI.0610-20.2020  0.731
2020 Soria FN, Paviolo C, Doudnikoff E, Arotcarena ML, Lee A, Danné N, Mandal AK, Gosset P, Dehay B, Groc L, Cognet L, Bezard E. Synucleinopathy alters nanoscale organization and diffusion in the brain extracellular space through hyaluronan remodeling. Nature Communications. 11: 3440. PMID 32651387 DOI: 10.1038/S41467-020-17328-9  0.637
2020 Maxan A, Sciacca G, Alpaugh M, Tao Z, Breger L, Dehay B, Ling Z, Qin C, Cisbani G, Masnata M, Salem S, Lacroix S, Oueslati A, Bezard E, Cicchetti F. Use of adeno-associated virus-mediated delivery of mutant huntingtin to study the spreading capacity of the protein in mice and non-human primates. Neurobiology of Disease. 104951. PMID 32439599 DOI: 10.1016/J.Nbd.2020.104951  0.638
2020 Bourdenx M, Nioche A, Dovero S, Arotcarena ML, Camus S, Porras G, Thiolat ML, Rougier NP, Prigent A, Aubert P, Bohic S, Sandt C, Laferrière F, Doudnikoff E, Kruse N, ... ... Bezard E, et al. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates. Science Advances. 6: eaaz9165. PMID 32426502 DOI: 10.1126/Sciadv.Aaz9165  0.818
2020 Eshraghi M, Ramírez-Jarquín UN, Shahani N, Nuzzo T, De Rosa A, Swarnkar S, Galli N, Rivera O, Tsaprailis G, Scharager-Tapia C, Crynen G, Li Q, Thiolat ML, Bezard E, Usiello A, et al. RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease. Science Advances. 6: eaaz7001. PMID 32426479 DOI: 10.1126/sciadv.aaz7001  0.437
2020 Gosset P, Maxan A, Alpaugh M, Breger L, Dehay B, Tao Z, Ling Z, Qin C, Cisbani G, Fortin N, Vonsattel JG, Lacroix S, Oueslati A, Bezard E, Cicchetti F. Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates. Neurobiology of Disease. 104941. PMID 32422281 DOI: 10.1016/J.Nbd.2020.104941  0.658
2020 Arotcarena ML, Dovero S, Prigent A, Bourdenx M, Camus S, Porras G, Thiolat ML, Tasselli M, Aubert P, Kruse N, Mollenhauer B, Damas IT, Estrada C, Garcia-Carrillo N, Vaikath NN, ... ... Bezard E, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain : a Journal of Neurology. PMID 32380543 DOI: 10.1093/Brain/Awaa096  0.826
2020 Deffains M, Haï Nguyen T, Orignac H, Biendon N, Dovero S, Bezard E, Boraud T. In vivo electrophysiological validation of DREADD-based modulation of pallidal neurons in the non-human primate. The European Journal of Neuroscience. PMID 32306446 DOI: 10.1111/Ejn.14746  0.783
2020 Lopez-Cuina M, Guerin PA, Canron MH, Delamarre A, Dehay B, Bezard E, Meissner WG, Fernagut PO. Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 32291831 DOI: 10.1002/Mds.28034  0.788
2020 Moreau C, Rolland AS, Pioli E, Li Q, Odou P, Barthelemy C, Lannoy D, Demailly A, Carta N, Deramecourt V, Auger F, Kuchcinski G, Laloux C, Defebvre L, Bordet R, ... ... Bezard E, et al. Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease. Neurobiology of Disease. 104846. PMID 32205254 DOI: 10.1016/j.nbd.2020.104846  0.476
2020 Teil M, Arotcarena ML, Faggiani E, Laferriere F, Bezard E, Dehay B. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules. 10. PMID 32138193 DOI: 10.3390/biom10030391  0.662
2020 Faivre F, Sánchez-Catalán MJ, Dovero S, Bido S, Joshi A, Bezard E, Barrot M. Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson's disease. Neurobiology of Disease. 104818. PMID 32087289 DOI: 10.1016/j.nbd.2020.104818  0.74
2020 Ribot B, Aupy J, Vidailhet M, Mazère J, Pisani A, Bezard E, Guehl D, Burbaud P. Corrigendum to "Dystonia and dopamine: From phenomenology to pathophysiology" [Prog. Neurobiol. 182 (November) (2019), 101678, 18]. Progress in Neurobiology. 101745. PMID 31928793 DOI: 10.1016/J.Pneurobio.2019.101745  0.612
2020 Hulme H, Fridjonsdottir E, Gunnarsdottir H, Vallianatou T, Zhang X, Wadensten H, Shariatgorji R, Nilsson A, Bezard E, Svenningsson P, Andrén PE. Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy. Neurobiology of Disease. 104738. PMID 31927144 DOI: 10.1016/j.nbd.2020.104738  0.423
2020 Bertin E, Deluc T, Pilch KS, Martinez A, Pougnet JT, Doudnikoff E, Allain AE, Bergmann P, Russeau M, Toulmé E, Bezard E, Koch-Nolte F, Séguéla P, Lévi S, Bontempi B, et al. Increased surface P2X4 receptor regulates anxiety and memory in P2X4 internalization-defective knock-in mice. Molecular Psychiatry. PMID 31911635 DOI: 10.1038/s41380-019-0641-8  0.326
2019 Bezard E. Models of hyperkinetic disorders in primates. Journal of Neuroscience Methods. 332: 108551. PMID 31857131 DOI: 10.1016/j.jneumeth.2019.108551  0.351
2019 Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O. Multiple System Atrophy: Recent Developments and Future Perspectives. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31692132 DOI: 10.1002/Mds.27894  0.785
2019 Dehay B, Bezard E. Intrastriatal injection of alpha-synuclein fibrils induces Parkinson-like pathology in macaques. Brain : a Journal of Neurology. 142: 3321-3322. PMID 31665750 DOI: 10.1093/Brain/Awz329  0.649
2019 Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M. Managing Parkinson's disease: Moving ON with NOP. British Journal of Pharmacology. PMID 31648371 DOI: 10.1111/Bph.14893  0.628
2019 Arotcarena ML, Bourdenx M, Dutheil N, Thiolat ML, Doudnikoff E, Dovero S, Ballabio A, Fernagut PO, Meissner WG, Bezard E, Dehay B. Transcription factor EB overexpression prevents neurodegeneration in experimental synucleinopathies. Jci Insight. 4. PMID 31434803 DOI: 10.1172/Jci.Insight.129719  0.826
2019 Ribot B, Aupy J, Vidailhet M, Mazère J, Pisani A, Bezard E, Guehl D, Burbaud P. Dystonia and dopamine: From phenomenology to pathophysiology. Progress in Neurobiology. 101678. PMID 31404592 DOI: 10.1016/J.Pneurobio.2019.101678  0.635
2019 Rosenblad C, Li Q, Pioli EY, Dovero S, Antunes ASLM, Agúndez L, Bardelli M, Linden RM, Henckaerts E, Björklund A, Bezard E, Björklund T. Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease. Brain : a Journal of Neurology. PMID 31243443 DOI: 10.1093/Brain/Awz176  0.744
2019 Nuzzo T, Punzo D, Devoto P, Rosini E, Paciotti S, Sacchi S, Li Q, Thiolat ML, Véga C, Carella M, Carta M, Gardoni F, Calabresi P, Pollegioni L, Bezard E, et al. The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. Scientific Reports. 9: 8898. PMID 31222058 DOI: 10.1038/S41598-019-45419-1  0.427
2019 Delamarre A, Tison F, Li Q, Galitzky M, Rascol O, Bezard E, Meissner WG. Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 31098725 DOI: 10.1007/s00702-019-02015-x  0.356
2019 Li Q, Fernagut PO, Bezard E. l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31083822 DOI: 10.1002/Mds.27715  0.662
2019 Thomasson N, Pioli E, Friedel C, Monseur A, Lavaur J, Moya KL, Bezard E, Bousseau A, Prochiantz A. Engrailed-1 induces long-lasting behavior benefit in an experimental Parkinson primate model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31077447 DOI: 10.1002/Mds.27714  0.337
2019 Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Sarna J, Monchi O, Duval C. Remnants of Cardinal Symptoms of Parkinson's Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Frontiers in Neurology. 10: 256. PMID 30967832 DOI: 10.3389/Fneur.2019.00256  0.372
2019 Laferrière F, Maniecka Z, Pérez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM, Wagner U, Afroz T, Boersema PJ, Barmettler G, Foti SC, Asi YT, Isaacs AM, Al-Amoudi A, Lewis A, ... ... Bezard E, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nature Neuroscience. 22: 65-77. PMID 30559480 DOI: 10.1038/S41593-018-0294-Y  0.363
2018 Bonsi P, Ponterio G, Vanni V, Tassone A, Sciamanna G, Migliarini S, Martella G, Meringolo M, Dehay B, Doudnikoff E, Zachariou V, Goodchild RE, Mercuri NB, D'Amelio M, Pasqualetti M, ... Bezard E, et al. RGS9-2 rescues dopamine D2 receptor levels and signaling in dystonia mouse models. Embo Molecular Medicine. PMID 30552094 DOI: 10.15252/Emmm.201809283  0.658
2018 Prevot G, Soria FN, Thiolat ML, Daniel J, Verlhac JB, Blanchard-Desce M, Bezard E, Barthelemy P, Crauste-Manciet S, Dehay B. Harnessing Lysosomal pH through PLGA Nanoemulsion as a Treatment of Lysosomal-related Neurodegenerative Diseases. Bioconjugate Chemistry. PMID 30424597 DOI: 10.1021/Acs.Bioconjchem.8B00697  0.655
2018 Faivre F, Joshi A, Bezard E, Barrot M. The hidden side of Parkinson's disease: studying pain, anxiety and depression in animal models. Neuroscience and Biobehavioral Reviews. PMID 30365972 DOI: 10.1016/j.neubiorev.2018.10.004  0.399
2018 Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE. Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts. Annals of Neurology. PMID 30357892 DOI: 10.1002/ana.25364  0.464
2018 Mellone M, Zianni E, Stanic J, Campanelli F, Marino G, Ghiglieri V, Longhi A, Thiolat ML, Li Q, Calabresi P, Bezard E, Picconi B, Di Luca M, Gardoni F. NMDA receptor GluN2D subunit participates to levodopa-induced dyskinesia pathophysiology. Neurobiology of Disease. PMID 30261285 DOI: 10.1016/j.nbd.2018.09.021  0.486
2018 Charvin D, Di Paolo T, Bezard E, Gregoire L, Takano A, Duvey G, Pioli E, Halldin C, Medori R, Conquet F. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30216534 DOI: 10.1002/Mds.27462  0.447
2018 Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice. Neurobiology of Disease. PMID 30172844 DOI: 10.1016/J.Nbd.2018.08.018  0.82
2018 Boland B, Yu WH, Corti O, Mollereau B, Henriques A, Bezard E, Pastores GM, Rubinsztein DC, Nixon RA, Duchen MR, Mallucci GR, Kroemer G, Levine B, Eskelinen EL, Mochel F, et al. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. Nature Reviews. Drug Discovery. PMID 30116051 DOI: 10.1038/Nrd.2018.109  0.355
2018 Chansel-Debordeaux L, Bourdenx M, Dutheil N, Dovero S, Canron MH, Jimenez C, Bezard E, Dehay B. Systemic gene delivery by single-dose intracardiac administration of scAAV2/9 and scAAV2/rh10 variants in newborn rats. Human Gene Therapy Methods. PMID 30064266 DOI: 10.1089/Hgtb.2017.192.R3  0.782
2018 Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiology of Disease. PMID 29936234 DOI: 10.1016/j.nbd.2018.06.019  0.384
2018 Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bézard E, Vincent C, Langlois M, Duval C. Cardinal Motor Features of Parkinson's Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia: Parkinson's Symptoms Coexist with Dyskinesia. Journal of Parkinson's Disease. PMID 29843253 DOI: 10.3233/Jpd-181312  0.43
2018 Baufreton J, Milekovic T, Li Q, McGuire S, Moraud EM, Porras G, Sun S, Ko WKD, Chazalon M, Morin S, Normand E, Farjot G, Milet A, Pype J, Pioli E, ... ... Bezard E, et al. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29756234 DOI: 10.1002/Mds.27404  0.449
2018 Iannielli A, Bido S, Folladori L, Segnali A, Cancellieri C, Maresca A, Massimino L, Rubio A, Morabito G, Caporali L, Tagliavini F, Musumeci O, Gregato G, Bezard E, Carelli V, et al. Pharmacological Inhibition of Necroptosis Protects from Dopaminergic Neuronal Cell Death in Parkinson's Disease Models. Cell Reports. 22: 2066-2079. PMID 29466734 DOI: 10.1016/j.celrep.2018.01.089  0.439
2017 Perez-Villalba A, Salomé Sirerol-Piquer M, Belenguer G, Soriano-Cantón R, Belén Muñoz-Manchado A, Villadiego J, Alarcón-Arís D, Soria FN, Dehay B, Bezard E, Vila M, Bortolozzi A, José Toledo-Aral J, Pérez-Sánchez F, Fariñas I. Synaptic regulator α-synuclein in dopaminergic fibers is essentially required for the maintenance of subependymal neural stem cells. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 29217686 DOI: 10.1523/Jneurosci.2276-17.2017  0.669
2017 Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, Burn D, Halliday GM, Bezard E, Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, Hallett M, DeLong MR, et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1264-1310. PMID 28887905 DOI: 10.1002/Mds.27115  0.614
2017 Chansel-Debordeaux L, Bourdenx M, Dovero S, Grouthier V, Dutheil N, Espana A, Groc L, Jimenez C, Bezard E, Dehay B. In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: towards new models of Parkinson's disease. Gene Therapy. 24: 801-809. PMID 28853717 DOI: 10.1038/Gt.2017.84  0.813
2017 Stanic J, Mellone M, Napolitano F, Racca C, Zianni E, Minocci D, Ghiglieri V, Thiolat ML, Li Q, Longhi A, De Rosa A, Picconi B, Bezard E, Calabresi P, Di Luca M, et al. Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiology of Disease. PMID 28823933 DOI: 10.1016/J.Nbd.2017.08.001  0.39
2017 Bido S, Soria FN, Fan RZ, Bezard E, Tieu K. Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease. Scientific Reports. 7: 7495. PMID 28790323 DOI: 10.1038/s41598-017-07181-0  0.356
2017 Ko WKD, Bezard E. Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to α-synuclein targeted disease modification. Experimental Neurology. PMID 28764902 DOI: 10.1016/j.expneurol.2017.07.020  0.433
2017 Napolitano F, Booth Warren E, Migliarini S, Punzo D, Errico F, Li Q, Thiolat ML, Vescovi AL, Calabresi P, Bezard E, Morelli M, Konradi C, Pasqualetti M, Usiello A. Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques. Plos One. 12: e0181677. PMID 28742811 DOI: 10.1371/Journal.Pone.0181677  0.466
2017 D Ko WK, Li Q, Yun Cheng L, Morelli M, Carta M, Bezard E. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease. European Journal of Pharmacology. PMID 28739086 DOI: 10.1016/J.Ejphar.2017.07.030  0.455
2017 Jávor-Duray BN, Vinck M, van der Roest M, Bezard E, Berendse HW, Boraud T, Voorn P. Alterations in functional cortical hierarchy in hemiparkinsonian rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28687605 DOI: 10.1523/Jneurosci.3257-16.2017  0.648
2017 Bassil F, Guerin PA, Dutheil N, Li Q, Klugmann M, Meissner WG, Bezard E, Fernagut PO. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28556404 DOI: 10.1002/Mds.27041  0.719
2017 Bastide MF, Glangetas C, Doudnikoff E, Li Q, Bourdenx M, Fernagut PO, Dumont ÉC, Georges F, Bézard E. Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia. Scientific Reports. 7: 2348. PMID 28539659 DOI: 10.1038/S41598-017-02572-9  0.829
2017 Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, Dehay B, Normand E, Vila M, Favereaux A, Georges F, Lo Bianco C, Bezard E, Fernagut PO. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics. PMID 28520872 DOI: 10.1093/Hmg/Ddx120  0.819
2017 Cavaliere F, Cerf L, Dehay B, Ramos-Gonzalez P, De Giorgi F, Bourdenx M, Bessede A, Obeso JA, Matute C, Ichas F, Bezard E. In vitro α-synuclein neurotoxicity and spreading among neurons and astrocytes using Lewy body extracts from Parkinson disease brains. Neurobiology of Disease. 103: 101-112. PMID 28411117 DOI: 10.1016/J.Nbd.2017.04.011  0.797
2017 Schmitt M, Dehay B, Bezard E, Garcia-Ladona FJ. U18666A, an Activator of Sterol Regulatory Element Binding Protein (SREBP) Pathway Modulates Presynaptic Dopaminergic Phenotype of SH-SY5Y Neuroblastoma Cells. Synapse (New York, N.Y.). PMID 28407359 DOI: 10.1002/Syn.21980  0.709
2017 Bourdenx M, Dovero S, Thiolat ML, Bezard E, Dehay B. Lack of spontaneous age-related brain pathology in Octodon degus: a reappraisal of the model. Scientific Reports. 7: 45831. PMID 28374864 DOI: 10.1038/Srep45831  0.81
2017 Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, Gulyani S, Kapogiannis D, Fernagut PO, Meissner WG. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain : a Journal of Neurology. PMID 28334990 DOI: 10.1093/Brain/Awx044  0.645
2017 Migdalska-Richards A, Ko WK, Li Q, Bezard E, Schapira AH. Oral ambroxol increases brain glucocerebrosidase activity in a non-human primate. Synapse (New York, N.Y.). PMID 28295625 DOI: 10.1002/syn.21967  0.392
2017 Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology. 16: 238-250. PMID 28229895 DOI: 10.1016/S1474-4422(17)30004-2  0.705
2017 Soria FN, Pampliega O, Bourdenx M, Meissner WG, Bezard E, Dehay B. Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. Frontiers in Neuroscience. 11: 26. PMID 28197068 DOI: 10.3389/Fnins.2017.00026  0.786
2017 Ysselstein D, Dehay B, Costantino IM, McCabe GP, Frosch MP, George JM, Bezard E, Rochet JC. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity. Acta Neuropathologica Communications. 5: 3. PMID 28069058 DOI: 10.1186/S40478-016-0403-7  0.637
2017 Charvin D, Di Paolo T, Bezard E, Halldin C, Duvey G, Gregoire L, Takano A, Pioli E, Medori R, Conquet F. A Novel mglur4 compound alleviates motor symptoms in primate models of parkinson's disease Journal of the Neurological Sciences. 381: 97. DOI: 10.1016/J.Jns.2017.08.316  0.38
2016 Migdalska-Richards A, Daly L, Bezard E, Schapira AH. Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Annals of Neurology. 80: 766-775. PMID 27859541 DOI: 10.1002/ana.24790  0.352
2016 Bassil F, Fernagut PO, Bezard E, Pruvost A, Leste-Lasserre T, Hoang QQ, Ringe D, Petsko GA, Meissner WG. Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proceedings of the National Academy of Sciences of the United States of America. PMID 27482103 DOI: 10.1073/Pnas.1609291113  0.686
2016 Ko WK, Camus SM, Li Q, Jianzhong Y, McGuire S, Pioli EY, Bezard E. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology. PMID 27424102 DOI: 10.1016/j.neuropharm.2016.07.012  0.408
2016 Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron. 90: 1139. PMID 27253449 DOI: 10.1016/J.Neuron.2016.05.017  0.325
2016 Engeln M, Ansquer S, Dugast E, Bezard E, Belin D, Fernagut PO. Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy. Neuropharmacology. PMID 27216859 DOI: 10.1016/J.Neuropharm.2016.05.013  0.834
2016 Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27214664 DOI: 10.1002/mds.26659  0.399
2016 Dehay B, Decressac M, Bourdenx M, Guadagnino I, Fernagut PO, Tamburrino A, Bassil F, Meissner WG, Bezard E. Targeting α-synuclein: Therapeutic options. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26926119 DOI: 10.1002/Mds.26568  0.819
2016 Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26871939 DOI: 10.1002/Mds.26475  0.432
2016 Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease. Neurobiology of Disease. PMID 26804029 DOI: 10.1016/J.Nbd.2016.01.016  0.793
2016 Thiollier T, Wu C, Contamin H, Li Q, Zhang J, Bezard E. Permeability of blood-brain barrier in macaque model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson disease. Synapse (New York, N.Y.). PMID 26799359 DOI: 10.1002/syn.21889  0.374
2016 Bourdenx M, Daniel J, Genin E, Soria FN, Blanchard-Desce M, Bezard E, Dehay B. Nanoparticles restore lysosomal acidification defects: Implication for Parkinson and other lysosomal-related diseases. Autophagy. 0. PMID 26761717 DOI: 10.1080/15548627.2015.1136769  0.813
2016 Sauvestre F, Dehay B, Bézard E, Martin-Négrier M. Étude des anomalies morphologiques mitochondriales dans des lignées cellulaires humaines mutées pour le gène parkin Morphologie. 100: 170-171. DOI: 10.1016/J.Morpho.2016.07.023  0.58
2015 Bastide MF, Bézard E. [L-dopa induced dyskinesia in Parkinson's disease]. Bulletin De L'AcadéMie Nationale De MéDecine. 199: 201-12. PMID 27476302  0.394
2015 Schmitt M, Dehay B, Bezard E, Garcia-Ladona FJ. Harnessing the Trophic and Modulatory Potential of Statins in a Dopaminergic Cell Line. Synapse (New York, N.Y.). PMID 26695835 DOI: 10.1002/Syn.21881  0.698
2015 Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Neuron. 88: 762-773. PMID 26590347 DOI: 10.1016/J.Neuron.2015.10.039  0.401
2015 Bourdenx M, Dovero S, De Deurwaerdère P, Li Q, Bezard E. Early Prenatal Exposure to MPTP Does Not Affect Nigrostrial Neurons in Macaque Monkey. Synapse (New York, N.Y.). PMID 26584009 DOI: 10.1002/Syn.21876  0.842
2015 Dovero S, Gross C, Bezard E. Unexpected toxicity of very low dose MPTP in mice: A clue to the aetiology of Parkinson's disease? Synapse (New York, N.Y.). PMID 26583879 DOI: 10.1002/syn.21875  0.817
2015 Bastide MF, Bido S, Duteil N, Bézard E. Striatal NELF-mediated RNA polymerase II stalling controls l-dopa induced dyskinesia. Neurobiology of Disease. 85: 93-98. PMID 26480869 DOI: 10.1016/j.nbd.2015.10.013  0.356
2015 Dehay B, Vila M, Bezard E, Brundin P, Kordower JH. Alpha-synuclein propagation: New insights from animal models. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26347034 DOI: 10.1002/Mds.26370  0.647
2015 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/J.Pneurobio.2015.07.002  0.815
2015 Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology. PMID 26209472 DOI: 10.1016/J.Pneurobio.2015.07.003  0.806
2015 Bourdenx M, Dovero S, Engeln M, Bido S, Bastide MF, Dutheil N, Vollenweider I, Baud L, Piron C, Grouthier V, Boraud T, Porras G, Li Q, Baekelandt V, Scheller D, ... ... Bezard E, et al. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathologica Communications. 3: 46. PMID 26205255 DOI: 10.1186/S40478-015-0222-2  0.823
2015 Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. The Lancet. Neurology. PMID 26050140 DOI: 10.1016/S1474-4422(15)00006-X  0.821
2015 Abdi A, Mallet N, Mohamed FY, Sharott A, Dodson PD, Nakamura KC, Suri S, Avery SV, Larvin JT, Garas FN, Garas SN, Vinciati F, Morin S, Bezard E, Baufreton J, et al. Prototypic and arkypallidal neurons in the dopamine-intact external globus pallidus. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 6667-88. PMID 25926446 DOI: 10.1523/Jneurosci.4662-14.2015  0.385
2015 Urs NM, Bido S, Peterson SM, Daigle TL, Bass CE, Gainetdinov RR, Bezard E, Caron MG. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 112: E2517-26. PMID 25918399 DOI: 10.1073/Pnas.1502740112  0.467
2015 Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neuroscience. 298: 389-96. PMID 25907446 DOI: 10.1016/J.Neuroscience.2015.04.027  0.419
2015 Barroso-Chinea P, Thiolat ML, Bido S, Martinez A, Doudnikoff E, Baufreton J, Bourdenx M, Bloch B, Bezard E, Martin-Negrier ML. D1 dopamine receptor stimulation impairs striatal proteasome activity in Parkinsonism through 26S proteasome disassembly. Neurobiology of Disease. 78: 77-87. PMID 25766677 DOI: 10.1016/J.Nbd.2015.02.024  0.761
2015 Bezard E, Carta M. Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? Brain : a Journal of Neurology. 138: 829-30. PMID 25669729 DOI: 10.1093/Brain/Awu407  0.32
2015 Bourdenx M, Dehay B, Bezard E. Modélisation expérimentale de l’agrégation et de la propagation de l’α-synucléine dans les synucléinopathies Bulletin De L'AcadéMie Nationale De MéDecine. 199: 797-808. DOI: 10.1016/S0001-4079(19)30882-9  0.751
2014 Shariatgorji M, Nilsson A, Goodwin RJ, Källback P, Schintu N, Zhang X, Crossman AR, Bezard E, Svenningsson P, Andren PE. Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections. Neuron. 84: 697-707. PMID 25453841 DOI: 10.1016/J.Neuron.2014.10.011  0.69
2014 Bastide MF, de la Crompe B, Doudnikoff E, Fernagut PO, Gross CE, Mallet N, Boraud T, Bézard E. Inhibiting Lateral Habenula Improves L-DOPA-induced Dyskinesia. Biological Psychiatry. PMID 25442003 DOI: 10.1016/J.Biopsych.2014.08.022  0.812
2014 Charron G, Doudnikoff E, Canron MH, Li Q, Véga C, Marais S, Baufreton J, Vital A, Oliet SH, Bezard E. Astrocytosis in parkinsonism: considering tripartite striatal synapses in physiopathology? Frontiers in Aging Neuroscience. 6: 258. PMID 25309435 DOI: 10.3389/fnagi.2014.00258  0.427
2014 Bourdenx M, Dehay B, Bezard E. Down-regulating α-synuclein for treating synucleopathies. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1463-5. PMID 25214445 DOI: 10.1002/Mds.26028  0.764
2014 Bourdenx M, Bezard E, Dehay B. Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death. Frontiers in Neuroanatomy. 8: 83. PMID 25177278 DOI: 10.3389/Fnana.2014.00083  0.824
2014 Engeln M, Bastide MF, Toulmé E, Dehay B, Bourdenx M, Doudnikoff E, Li Q, Gross CE, Boué-Grabot E, Pisani A, Bezard E, Fernagut PO. Selective Inactivation of Striatal FosB/ΔFosB-Expressing Neurons Alleviates L-Dopa-Induced Dyskinesia. Biological Psychiatry. PMID 25146322 DOI: 10.1016/J.Biopsych.2014.07.007  0.815
2014 Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of Disease. 70: 138-48. PMID 24969021 DOI: 10.1016/j.nbd.2014.06.013  0.754
2014 Schapira AH, Olanow CW, Greenamyre JT, Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet (London, England). 384: 545-55. PMID 24954676 DOI: 10.1016/S0140-6736(14)61010-2  0.394
2014 Bourdenx M, Dutheil N, Bezard E, Dehay B. Systemic gene delivery to the central nervous system using Adeno-associated virus. Frontiers in Molecular Neuroscience. 7: 50. PMID 24917785 DOI: 10.3389/Fnmol.2014.00050  0.77
2014 Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O, Poli SM. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1074-9. PMID 24865335 DOI: 10.1002/mds.25920  0.393
2014 Engeln M, De Deurwaerdère P, Li Q, Bezard E, Fernagut PO. Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia. Cerebral Cortex (New York, N.Y. : 1991). PMID 24770706 DOI: 10.1093/cercor/bhu076  0.82
2014 Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Pavy-Le Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner WG. Multiple system atrophy: a prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiology of Disease. 67: 133-9. PMID 24727096 DOI: 10.1016/J.Nbd.2014.03.021  0.79
2014 Ko WK, Pioli E, Li Q, McGuire S, Dufour A, Sherer TB, Bezard E, Facheris MF. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 772-9. PMID 24610195 DOI: 10.1002/mds.25859  0.414
2014 Bassil F, Fernagut PO, Bezard E, Meissner WG. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Progress in Neurobiology. 118: 1-18. PMID 24582776 DOI: 10.1016/J.Pneurobio.2014.02.005  0.656
2014 Ko WK, Li Q, Bezard E. Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease. Neuroscience Letters. 566: 72-6. PMID 24572591 DOI: 10.1016/j.neulet.2014.02.027  0.387
2014 Porras G, De Deurwaerdere P, Li Q, Marti M, Morgenstern R, Sohr R, Bezard E, Morari M, Meissner WG. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific Reports. 4: 3730. PMID 24429495 DOI: 10.1038/Srep03730  0.618
2014 Bezard E, Fernagut PO. Premotor parkinsonism models. Parkinsonism & Related Disorders. 20: S17-9. PMID 24262174 DOI: 10.1016/S1353-8020(13)70007-5  0.67
2014 Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut PO, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bezard E, Vila M. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Annals of Neurology. 75: 351-62. PMID 24243558 DOI: 10.1002/Ana.24066  0.833
2014 Hyacinthe C, Barraud Q, Tison F, Bezard E, Ghorayeb I. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiology of Disease. 63: 20-4. PMID 24211719 DOI: 10.1016/J.Nbd.2013.10.029  0.352
2014 Bourdenx M, Nilsson A, Wadensten H, Fälth M, Li Q, Crossman AR, Andrén PE, Bezard E. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease. 62: 307-12. PMID 24148855 DOI: 10.1016/J.Nbd.2013.10.016  0.807
2014 Porras G, Dehay B, Bezard E. Viral vectors in primate research: Examples from Parkinson’s disease research Neuromethods. 82: 331-341. DOI: 10.1007/978-1-62703-610-8_17  0.56
2013 Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neuroscience Research. 77: 242-6. PMID 24135129 DOI: 10.1016/J.Neures.2013.10.002  0.497
2013 Dupuis JP, Feyder M, Miguelez C, Garcia L, Morin S, Choquet D, Hosy E, Bezard E, Fisone G, Bioulac BH, Baufreton J. Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonism. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 14331-41. PMID 24005286 DOI: 10.1523/Jneurosci.1681-13.2013  0.736
2013 Dehay B, Martinez-Vicente M, Caldwell GA, Caldwell KA, Yue Z, Cookson MR, Klein C, Vila M, Bezard E. Lysosomal impairment in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 725-32. PMID 23580333 DOI: 10.1002/Mds.25462  0.748
2013 Engeln M, Fasano S, Ahmed SH, Cador M, Baekelandt V, Bezard E, Fernagut PO. Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Annals of Neurology. 74: 140-4. PMID 23494678 DOI: 10.1002/Ana.23881  0.833
2013 Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1088-96. PMID 23389842 DOI: 10.1002/Mds.25366  0.44
2013 Tison F, Nègre-Pagès L, Meissner WG, Dupouy S, Li Q, Thiolat ML, Thiollier T, Galitzky M, Ory-Magne F, Milhet A, Marquine L, Spampinato U, Rascol O, Bezard E. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Parkinsonism & Related Disorders. 19: 416-21. PMID 23283428 DOI: 10.1016/j.parkreldis.2012.12.003  0.356
2013 Schneider JS, Pioli EY, Jianzhong Y, Li Q, Bezard E. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 663-7. PMID 23238827 DOI: 10.1002/mds.25258  0.371
2013 Bezard E. Experimental reappraisal of continuous dopaminergic stimulation against L-dopa-induced dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1021-2. PMID 23143999 DOI: 10.1002/mds.25251  0.457
2013 Engeln M, Ahmed SH, Vouillac C, Tison F, Bezard E, Fernagut PO. Reinforcing properties of Pramipexole in normal and parkinsonian rats. Neurobiology of Disease. 49: 79-86. PMID 22940424 DOI: 10.1016/J.Nbd.2012.08.005  0.81
2013 Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 61-70. PMID 22753348 DOI: 10.1002/Mds.25108  0.457
2012 Tass PA, Qin L, Hauptmann C, Dovero S, Bezard E, Boraud T, Meissner WG. Coordinated reset has sustained aftereffects in Parkinsonian monkeys. Annals of Neurology. 72: 816-20. PMID 23280797 DOI: 10.1002/ana.23663  0.802
2012 Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 16106-19. PMID 23152595 DOI: 10.1523/Jneurosci.6408-11.2012  0.55
2012 Porras G, Berthet A, Dehay B, Li Q, Ladepeche L, Normand E, Dovero S, Martinez A, Doudnikoff E, Martin-Négrier ML, Chuan Q, Bloch B, Choquet D, Boué-Grabot E, Groc L, ... Bezard E, et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. The Journal of Clinical Investigation. 122: 3977-89. PMID 23041629 DOI: 10.1172/Jci59426  0.808
2012 Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1373-8. PMID 22976821 DOI: 10.1002/mds.25133  0.706
2012 Miguelez C, Morin S, Martinez A, Goillandeau M, Bezard E, Bioulac B, Baufreton J. Altered pallido-pallidal synaptic transmission leads to aberrant firing of globus pallidus neurons in a rat model of Parkinson's disease. The Journal of Physiology. 590: 5861-75. PMID 22890706 DOI: 10.1113/jphysiol.2012.241331  0.693
2012 Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, Bezard E. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy. 8: 1389-91. PMID 22885599 DOI: 10.4161/Auto.21011  0.691
2012 Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron MH, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 109: 9611-6. PMID 22647602 DOI: 10.1073/Pnas.1112368109  0.699
2012 Porras G, Li Q, Bezard E. Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harbor Perspectives in Medicine. 2: a009308. PMID 22393538 DOI: 10.1101/cshperspect.a009308  0.414
2012 Dehay B, Dalkara D, Dovero S, Li Q, Bezard E. Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques. Scientific Reports. 2: 253. PMID 22355765 DOI: 10.1038/Srep00253  0.775
2012 Berthet A, Bezard E, Porras G, Fasano S, Barroso-Chinea P, Dehay B, Martinez A, Thiolat ML, Nosten-Bertrand M, Giros B, Baufreton J, Li Q, Bloch B, Martin-Negrier ML. L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 681-91. PMID 22238104 DOI: 10.1523/Jneurosci.1541-11.2012  0.72
2012 Keywood C, Bezard E, Hill M, Li Q, Girard F, Poli S, Mutel V. 2.231 ADX48621, A MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ALLEVIATES L-DOPA-INDUCED CHOREA AND DYSTONIA IN THE MPTP MACAQUE MODEL OF PARKINSON'S DISEASE Parkinsonism & Related Disorders. 18: S122. DOI: 10.1016/S1353-8020(11)70555-7  0.439
2012 Bezard E, Pisani A, Berton O. Neuroscience disease models Neuroscience. 211: 1. DOI: 10.1016/j.neuroscience.2012.04.022  0.326
2012 Bezard E. Animal models of Parkinson's disease Neurophysiologie Clinique/Clinical Neurophysiology. 42: 77. DOI: 10.1016/j.neucli.2011.11.019  0.418
2011 Tass PA, Qin L, Hauptmann C, Dovero S, Bezard E, Boraud T, Meissner WG. The translational value of the MPTP non-human primate model of Parkinsonism for deep brain stimulation research. Conference Proceedings : ... Annual International Conference of the Ieee Engineering in Medicine and Biology Society. Ieee Engineering in Medicine and Biology Society. Annual Conference. 2011: 663-6. PMID 22254396 DOI: 10.1109/IEMBS.2011.6090148  0.793
2011 Dehay B, Bezard E. New animal models of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1198-1205. PMID 22046592 DOI: 10.1002/Mds.23546  0.71
2011 Fisone G, Bezard E. Molecular mechanisms of l-DOPA-induced dyskinesia. International Review of Neurobiology. 98: 95-122. PMID 21907084 DOI: 10.1016/B978-0-12-381328-2.00004-3  0.464
2011 Gonon F, Bezard E, Boraud T. What should be said to the lay public regarding ADHD etiology. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 156: 989-91. PMID 21882340 DOI: 10.1002/Ajmg.B.31236  0.55
2011 Carta M, Bezard E. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience. 198: 245-51. PMID 21840375 DOI: 10.1016/J.Neuroscience.2011.07.070  0.42
2011 Charron G, Doudnikoff E, Laux A, Berthet A, Porras G, Canron MH, Barroso-Chinea P, Li Q, Qin C, Nosten-Bertrand M, Giros B, Delalande F, Van Dorsselaer A, Vital A, Goumon Y, ... Bezard E, et al. Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain : a Journal of Neurology. 134: 2321-38. PMID 21742735 DOI: 10.1093/Brain/Awr166  0.437
2011 Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 993-1002. PMID 21626544 DOI: 10.1002/Mds.23696  0.643
2011 Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E. Priorities in Parkinson's disease research. Nature Reviews. Drug Discovery. 10: 377-93. PMID 21532567 DOI: 10.1038/Nrd3430  0.438
2011 Gonon F, Bezard E, Boraud T. Misrepresentation of neuroscience data might give rise to misleading conclusions in the media: the case of attention deficit hyperactivity disorder. Plos One. 6: e14618. PMID 21297951 DOI: 10.1371/Journal.Pone.0014618  0.584
2011 Leger F, Fernagut PO, Canron MH, Léoni S, Vital C, Tison F, Bezard E, Vital A. Protein aggregation in the aging retina. Journal of Neuropathology and Experimental Neurology. 70: 63-8. PMID 21157377 DOI: 10.1097/Nen.0B013E31820376Cc  0.629
2010 Fernagut PO, Li Q, Dovero S, Chan P, Wu T, Ravenscroft P, Hill M, Chen Z, Bezard E. Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. Plos One. 5: e14053. PMID 21124922 DOI: 10.1371/Journal.Pone.0014053  0.81
2010 Fasano S, Bezard E, D'Antoni A, Francardo V, Indrigo M, Qin L, Doveró S, Cerovic M, Cenci MA, Brambilla R. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proceedings of the National Academy of Sciences of the United States of America. 107: 21824-9. PMID 21115823 DOI: 10.1073/Pnas.1012071107  0.334
2010 Barraud Q, Obeid I, Aubert I, Barrière G, Contamin H, McGuire S, Ravenscroft P, Porras G, Tison F, Bezard E, Ghorayeb I. Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. Plos One. 5: e13306. PMID 20967255 DOI: 10.1371/Journal.Pone.0013306  0.345
2010 Barroso-Chinea P, Bezard E. Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Frontiers in Neuroanatomy. 4. PMID 20890450 DOI: 10.3389/fnana.2010.00131  0.416
2010 Rylander D, Parent M, O'Sullivan SS, Dovero S, Lees AJ, Bezard E, Descarries L, Cenci MA. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Annals of Neurology. 68: 619-28. PMID 20882603 DOI: 10.1002/Ana.22097  0.727
2010 Fernagut PO, Barraud Q, Bezard E, Ghorayeb I, Tison F. Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism. Neurological Research. 32: 1050-3. PMID 20810027 DOI: 10.1179/016164110X12807570509934  0.729
2010 Santini E, Sgambato-Faure V, Li Q, Savasta M, Dovero S, Fisone G, Bezard E. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. Plos One. 5: e12322. PMID 20808799 DOI: 10.1371/Journal.Pone.0012322  0.706
2010 Rylander D, Iderberg H, Li Q, Dekundy A, Zhang J, Li H, Baishen R, Danysz W, Bezard E, Cenci MA. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiology of Disease. 39: 352-61. PMID 20452425 DOI: 10.1016/J.Nbd.2010.05.001  0.438
2010 Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E. Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Science Translational Medicine. 2: 28ra28. PMID 20410529 DOI: 10.1126/Scitranslmed.3000664  0.846
2010 Storvik M, Arguel MJ, Schmieder S, Delerue-Audegond A, Li Q, Qin C, Vital A, Bioulac B, Gross CE, Wong G, Nahon JL, Bezard E. Genes regulated in MPTP-treated macaques and human Parkinson's disease suggest a common signature in prefrontal cortex. Neurobiology of Disease. 38: 386-94. PMID 20206263 DOI: 10.1016/J.Nbd.2010.02.008  0.824
2010 Bezard E. Treating Parkinson's disease: preserve the spines! (Commentary on Soderstrom et al.). The European Journal of Neuroscience. 31: 477. PMID 20105227 DOI: 10.1111/j.1460-9568.2010.07117.x  0.423
2010 Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (New York, N.Y.). 64: 177-80. PMID 19852073 DOI: 10.1002/syn.20739  0.653
2010 Bezard E, Porras G, Blesa J, Obeso JA. Chapter 37 - Compensatory Mechanisms in Experimental and Human Parkinsonism: Potential for New Therapies Handbook of Behavioral Neuroscience. 20: 641-652. DOI: 10.1016/B978-0-12-374767-9.00037-8  0.469
2009 Berthet A, Bezard E. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & Related Disorders. 15: S8-12. PMID 20123563 DOI: 10.1016/S1353-8020(09)70827-2  0.436
2009 Guigoni C, Bezard E. Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia. Parkinsonism & Related Disorders. 15: S64-7. PMID 20083011 DOI: 10.1016/S1353-8020(09)70783-7  0.422
2009 Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. The Lancet. Neurology. 8: 1140-9. PMID 19909912 DOI: 10.1016/S1474-4422(09)70287-X  0.703
2009 Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. The Lancet. Neurology. 8: 1128-39. PMID 19909911 DOI: 10.1016/S1474-4422(09)70293-5  0.46
2009 Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, Ghorayeb I. Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Experimental Neurology. 219: 574-82. PMID 19635479 DOI: 10.1016/J.Expneurol.2009.07.019  0.681
2009 Vital A, Fernagut PO, Canron MH, Joux J, Bezard E, Martin-Negrier ML, Vital C, Tison F. The nigrostriatal pathway in Creutzfeldt-Jakob disease. Journal of Neuropathology and Experimental Neurology. 68: 809-15. PMID 19535991 DOI: 10.1097/Nen.0B013E3181Abdae8  0.711
2009 Reese R, Charron G, Nadjar A, Aubert I, Thiolat ML, Hamann M, Richter A, Bezard E, Meissner WG. High frequency stimulation of the entopeduncular nucleus sets the cortico-basal ganglia network to a new functional state in the dystonic hamster. Neurobiology of Disease. 35: 399-405. PMID 19501651 DOI: 10.1016/j.nbd.2009.05.022  0.304
2009 Berton O, Guigoni C, Li Q, Bioulac BH, Aubert I, Gross CE, Dileone RJ, Nestler EJ, Bezard E. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biological Psychiatry. 66: 554-61. PMID 19481198 DOI: 10.1016/J.Biopsych.2009.04.005  0.826
2009 Berthet A, Porras G, Doudnikoff E, Stark H, Cador M, Bezard E, Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 4829-35. PMID 19369551 DOI: 10.1523/Jneurosci.5884-08.2009  0.327
2009 Schuster S, Doudnikoff E, Rylander D, Berthet A, Aubert I, Ittrich C, Bloch B, Cenci MA, Surmeier DJ, Hengerer B, Bezard E. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biological Psychiatry. 65: 518-26. PMID 18947822 DOI: 10.1016/J.Biopsych.2008.09.008  0.412
2009 Nadjar A, Gerfen CR, Bezard E. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Progress in Neurobiology. 87: 1-9. PMID 18938208 DOI: 10.1016/j.pneurobio.2008.09.013  0.478
2009 Nadjar A, Berton O, Guo S, Leneuve P, Dovero S, Diguet E, Tison F, Zhao B, Holzenberger M, Bezard E. IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP. Neurobiology of Aging. 30: 2021-30. PMID 18394756 DOI: 10.1016/j.neurobiolaging.2008.02.009  0.689
2009 Barraud Q, Lambrecq V, Forni C, Balzamo E, McGuire S, Hill M, Bioulac B, Bezard E, Tison F, Ghorayeb I. P3.172 Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model Parkinsonism & Related Disorders. 15. DOI: 10.1016/S1353-8020(09)70736-9  0.334
2009 Rylander D, Li Q, Dekundy A, Li H, Baishen R, Danysz W, Bezard E, Cenci A. P2.157 Metabotropic glutamate receptor type 5 (mGluR5) antagonists improve L-DOPA-induced-dyskinesia in both rat and macaque models of Parkinson's disease Parkinsonism & Related Disorders. 15: S132. DOI: 10.1016/S1353-8020(09)70508-5  0.395
2009 Hill M, Decamp E, Bezard E, Li Q, Schneider J, Crossman A. P2.010 Progressive MPTP non-human primate models that recapitulate non-motor symptoms of Parkinson's disease Parkinsonism & Related Disorders. 15: S90-S91. DOI: 10.1016/S1353-8020(09)70361-X  0.724
2009 Schneider JS, Decamp E, Hill M, Bezard E, Crossman A, Murphy B, Mocaer E, Thomasson-Perret N. P4-342: Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction Alzheimer's & Dementia. 5: e31-e31. DOI: 10.1016/j.jalz.2009.07.140  0.665
2008 Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain : a Journal of Neurology. 131: 3380-94. PMID 18952677 DOI: 10.1093/Brain/Awn235  0.376
2008 Pioli EY, Meissner W, Sohr R, Gross CE, Bezard E, Bioulac BH. Differential behavioral effects of partial bilateral lesions of ventral tegmental area or substantia nigra pars compacta in rats. Neuroscience. 153: 1213-24. PMID 18455318 DOI: 10.1016/j.neuroscience.2008.01.084  0.796
2008 Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, Bezard E. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 4311-6. PMID 18434508 DOI: 10.1523/JNEUROSCI.4720-07.2008  0.439
2008 Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. Journal of Neurochemistry. 106: 486-94. PMID 18410512 DOI: 10.1111/j.1471-4159.2008.05417.x  0.69
2008 Scholz B, Svensson M, Alm H, Sköld K, Fälth M, Kultima K, Guigoni C, Doudnikoff E, Li Q, Crossman AR, Bezard E, Andrén PE. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. Plos One. 3: e1589. PMID 18270577 DOI: 10.1371/Journal.Pone.0001589  0.734
2008 Scheller D, Stichel-Gunkel C, Lübbert H, Porras G, Ravenscroft P, Hill M, Bezard E. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's disease. Neuroscience Letters. 432: 30-4. PMID 18162314 DOI: 10.1016/j.neulet.2007.12.001  0.473
2008 Porras G, Bezard E. Preclinical development of gene therapy for Parkinson's disease. Experimental Neurology. 209: 72-81. PMID 17904121 DOI: 10.1016/j.expneurol.2007.08.003  0.375
2007 Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C, LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E. RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 14338-48. PMID 18160641 DOI: 10.1523/Jneurosci.4223-07.2007  0.745
2007 Belujon P, Bezard E, Taupignon A, Bioulac B, Benazzouz A. Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 9595-606. PMID 17804620 DOI: 10.1523/JNEUROSCI.2583-07.2007  0.708
2007 Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biological Psychiatry. 62: 1353-62. PMID 17624318 DOI: 10.1016/j.biopsych.2007.04.020  0.447
2007 Meissner W, Guigoni C, Cirilli L, Garret M, Bioulac BH, Gross CE, Bezard E, Benazzouz A. Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. The European Journal of Neuroscience. 25: 1492-500. PMID 17425575 DOI: 10.1111/J.1460-9568.2007.05406.X  0.803
2007 Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiology of Disease. 26: 452-63. PMID 17350277 DOI: 10.1016/J.Nbd.2007.02.001  0.419
2007 Pasquereau B, Nadjar A, Arkadir D, Bezard E, Goillandeau M, Bioulac B, Gross CE, Boraud T. Shaping of motor responses by incentive values through the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 1176-83. PMID 17267573 DOI: 10.1523/Jneurosci.3745-06.2007  0.796
2007 Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Experimental Neurology. 203: 415-22. PMID 17045989 DOI: 10.1016/J.Expneurol.2006.08.026  0.743
2007 Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, Crossman AR, Bloch B, Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biological Psychiatry. 61: 836-44. PMID 16950226 DOI: 10.1016/J.Biopsych.2006.06.038  0.784
2007 Schuster S, Nadjar A, Guo J, Li Q, Ittrich C, Hengerer B, Bezard E. 2.508 The HMG-CoA reductase inhibitor lovastatin reduces incidence of L-Dopa-induced abnormal involuntary movements in experimental Parkinson's disease Parkinsonism & Related Disorders. 13: S144. DOI: 10.1016/S1353-8020(08)70782-X  0.414
2007 Bezard E, Gold S, Hoang C, Porras G, Waugh J, Neve R. 2.502 RGS9−2 negatively modulates L-dopa-induced dyskinesia in experimental Parkinson's disease Parkinsonism & Related Disorders. 13: S143. DOI: 10.1016/S1353-8020(08)70776-4  0.429
2007 Bezard E, Berton O, Guigoni C, Dovero S, Kumar A, McClung C, DiLeone R, Nestler E. 2.501 Role of DeltaFosB in the development of L-DOPA-induced dyskinesia in a non-human primate model of Parkinson's disease Parkinsonism & Related Disorders. 13: S142. DOI: 10.1016/S1353-8020(08)70775-2  0.436
2006 Kultima K, Scholz B, Alm H, Sköld K, Svensson M, Crossman AR, Bezard E, Andrén PE, Lönnstedt I. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. Bmc Bioinformatics. 7: 475. PMID 17067368 DOI: 10.1186/1471-2105-7-475  0.695
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087  0.759
2006 Li Q, Zhao D, Bezard E. Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature. Behavioural Pharmacology. 17: 403-10. PMID 16940761 DOI: 10.1097/00008877-200609000-00006  0.404
2006 Bezard E. A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behavioural Pharmacology. 17: 379-82. PMID 16940758 DOI: 10.1097/00008877-200609000-00003  0.332
2006 Leblois A, Meissner W, Bezard E, Bioulac B, Gross CE, Boraud T. Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys. The European Journal of Neuroscience. 24: 1201-8. PMID 16930445 DOI: 10.1111/J.1460-9568.2006.04984.X  0.805
2006 Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 8653-61. PMID 16928853 DOI: 10.1523/Jneurosci.2582-06.2006  0.828
2006 Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. Cns & Neurological Disorders Drug Targets. 5: 25-43. PMID 16613552 DOI: 10.2174/187152706784111551  0.684
2006 Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiology of Disease. 23: 77-86. PMID 16545572 DOI: 10.1016/J.Nbd.2006.02.003  0.749
2006 Meissner W, Ravenscroft P, Reese R, Harnack D, Morgenstern R, Kupsch A, Klitgaard H, Bioulac B, Gross CE, Bezard E, Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiology of Disease. 22: 586-98. PMID 16531050 DOI: 10.1016/j.nbd.2006.01.009  0.823
2006 Bezard E. S3 PATHOPHYSIOLOGY OF LEVODOPA-INDUCED DYSKINESIA IN PARKINSON??S DISEASE: OPPORTUNITIES FOR NOVEL TREATMENTS Behavioural Pharmacology. 17: 535. DOI: 10.1097/00008877-200609000-00022  0.415
2005 Ghorayeb I, Bezard E, Fernagut PO, Bioulac B, Tison F. [Animal models of parkinsonism]. Revue Neurologique. 161: 907-15. PMID 16365620 DOI: 10.1016/S0035-3787(05)85154-9  0.737
2005 Bassilana F, Mace N, Li Q, Stutzmann JM, Gross CE, Pradier L, Benavides J, Ménager J, Bezard E. Unraveling substantia nigra sequential gene expression in a progressive MPTP-lesioned macaque model of Parkinson's disease. Neurobiology of Disease. 20: 93-103. PMID 16137570 DOI: 10.1016/j.nbd.2005.02.005  0.712
2005 Guo S, Bezard E, Zhao B. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radical Biology & Medicine. 39: 682-95. PMID 16085186 DOI: 10.1016/j.freeradbiomed.2005.04.022  0.313
2005 Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, Gurevich EV, Gross CE, Bezard E. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. The European Journal of Neuroscience. 22: 283-7. PMID 16029219 DOI: 10.1111/J.1460-9568.2005.04196.X  0.809
2005 Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, HÃ¥kansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, ... ... Bezard E, et al. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism & Related Disorders. 11: S25-9. PMID 15885624 DOI: 10.1016/J.Parkreldis.2004.11.005  0.799
2005 Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008  0.821
2005 Guigoni C, Li Q, Aubert I, Dovero S, Bioulac BH, Bloch B, Crossman AR, Gross CE, Bezard E. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2102-7. PMID 15728850 DOI: 10.1523/Jneurosci.5059-04.2005  0.811
2005 Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Neurobiology of Disease. 18: 323-35. PMID 15686961 DOI: 10.1016/J.Nbd.2004.10.005  0.709
2005 Aubert I, Guigoni C, HÃ¥kansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology. 57: 17-26. PMID 15514976 DOI: 10.1002/Ana.20296  0.808
2005 Meissner W, Ravenscroft P, Reese R, Harnack D, Bioulac B, Gross C, Bezard E, Boraud T. L-DOPA induziert oszillierende Aktivität in der Substantia nigra Pars reticulata in einem Dyskinesiemodell der Ratte Aktuelle Neurologie. 32. DOI: 10.1055/s-2005-866657  0.796
2004 Pioli EY, Dovero S, Bioulac BH, Gross CE, Bezard E. Asymmetrically lesioned mesencephalon in healthy rodents: call for caution. Brain Research. 1022: 251-3. PMID 15353237 DOI: 10.1016/j.brainres.2004.07.014  0.817
2004 Pioli E, Sohr R, Meissner W, Barthe N, Gross CE, Bezard E, Bioulac BH. Partial bilateral mesencephalic lesions affect D1 but not D2 binding in both the striatum and cortex. Neurochemistry International. 45: 995-1004. PMID 15337298 DOI: 10.1016/j.neuint.2004.06.003  0.778
2004 Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clinical Neuropharmacology. 27: 171-7. PMID 15319703 DOI: 10.1097/01.wnf.0000135478.70905.3d  0.796
2004 Diguet E, Gross CE, Tison F, Bezard E. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Experimental Neurology. 189: 1-4. PMID 15296829 DOI: 10.1016/j.expneurol.2004.05.016  0.647
2004 Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics. 311: 770-7. PMID 15226382 DOI: 10.1124/jpet.104.071142  0.414
2004 Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. The European Journal of Neuroscience. 19: 3266-76. PMID 15217383 DOI: 10.1111/j.0953-816X.2004.03372.x  0.8
2004 Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends in Pharmacological Sciences. 25: 249-53. PMID 15120490 DOI: 10.1016/j.tips.2004.03.003  0.684
2004 Guillin O, Griffon N, Diaz J, Le Foll B, Bezard E, Gross C, Lammers C, Stark H, Carroll P, Schwartz JC, Sokoloff P. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. International Review of Neurobiology. 59: 425-44. PMID 15006497 DOI: 10.1016/S0074-7742(04)59016-5  0.661
2004 Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 386-94. PMID 15004218 DOI: 10.1124/jpet.104.066191  0.823
2004 Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485: 159-64. PMID 14757136 DOI: 10.1016/j.ejphar.2003.11.065  0.815
2004 Diguet E, Gross CE, Bezard E, Tison F, Stefanova N, Wenning GK. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 62: 158; author reply 15. PMID 14718729 DOI: 10.1212/Wnl.62.1.158  0.665
2004 Benazzouz A, Tai CH, Meissner W, Bioulac B, Bezard E, Gross C. High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 528-30. PMID 14715698 DOI: 10.1096/fj.03-0576fje  0.811
2004 Meissner W, Harnack D, Hoessle N, Bezard E, Winter C, Morgenstern R, Kupsch A. High frequency stimulation of the entopeduncular nucleus has no effect on striatal dopaminergic transmission. Neurochemistry International. 44: 281-6. PMID 14602091 DOI: 10.1016/S0197-0186(03)00138-4  0.397
2004 Bezard E, Gross CE, Brotchie JM. Response to Obeso et al.: Presymptomatic compensation in Parkinson's disease is not dopamine-mediated Trends in Neurosciences. 27: 127-128. DOI: 10.1016/j.tins.2003.12.005  0.791
2003 Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Molecular Neurobiology. 28: 209-18. PMID 14709785 DOI: 10.1385/Mn:28:3:209  0.75
2003 Bezard E, Dovero S, Belin D, Duconger S, Jackson-Lewis V, Przedborski S, Piazza PV, Gross CE, Jaber M. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 10999-1007. PMID 14657156 DOI: 10.1523/Jneurosci.23-35-10999.2003  0.815
2003 Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 1301-5. PMID 14639671 DOI: 10.1002/mds.10542  0.833
2003 Guillin O, Griffon N, Bezard E, Leriche L, Diaz J, Gross C, Sokoloff P. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. European Journal of Pharmacology. 480: 89-95. PMID 14623353 DOI: 10.1016/j.ejphar.2003.08.096  0.715
2003 Bezard E, Baufreton J, Owens G, Crossman AR, Dudek H, Taupignon A, Brotchie JM. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2337-8. PMID 14525941 DOI: 10.1096/fj.03-0291fje  0.824
2003 Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A. Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 1820-30. PMID 14519661 DOI: 10.1096/fj.03-0163com  0.814
2003 Bezard E. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design. The Lancet. Neurology. 2: 393. PMID 12849115 DOI: 10.1016/S1474-4422(03)00432-0  0.379
2003 Meissner W, Dovero S, Bioulac B, Gross CE, Bezard E. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiology of Disease. 13: 46-54. PMID 12758066 DOI: 10.1016/S0969-9961(03)00011-1  0.815
2003 Prunier C, Payoux P, Guilloteau D, Chalon S, Giraudeau B, Majorel C, Tafani M, Bezard E, Esquerré JP, Baulieu JL. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 44: 663-70. PMID 12732666  0.314
2003 Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends in Neurosciences. 26: 215-21. PMID 12689773 DOI: 10.1016/S0166-2236(03)00038-9  0.835
2003 Pioli EY, Gross CE, Meissner W, Bioulac BH, Bezard E. The deafferented nonhuman primate is not a reliable model of intractable pain. Neurological Research. 25: 127-9. PMID 12635510 DOI: 10.1179/016164103101201274  0.751
2003 Marvanová M, Ménager J, Bezard E, Bontrop RE, Pradier L, Wong G. Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 929-31. PMID 12626435 DOI: 10.1096/fj.02-0681fje  0.329
2003 Gross CE, Ravenscroft P, Dovero S, Jaber M, Bioulac B, Bezard E. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. Journal of Neurochemistry. 84: 1246-55. PMID 12614325 DOI: 10.1046/j.1471-4159.2003.01600.x  0.815
2002 Boraud T, Bezard E, Bioulac B, Gross CE. From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Progress in Neurobiology. 66: 265-83. PMID 11960681 DOI: 10.1016/S0301-0082(01)00033-8  0.822
2001 Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273 DOI: 10.1523/Jneurosci.21-17-06853.2001  0.833
2001 Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Reviews. Neuroscience. 2: 577-88. PMID 11484001 DOI: 10.1038/35086062  0.793
2001 Bezard E, Boraud T, Chalon S, Brotchie JM, Guilloteau D, Gross CE. Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience. 103: 117-23. PMID 11311792 DOI: 10.1016/S0306-4522(00)00546-7  0.812
2001 Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease. 8: 343-50. PMID 11300729 DOI: 10.1006/nbdi.2000.0375  0.84
2001 Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1092-4. PMID 11292678 DOI: 10.1096/Fj.00-0637Fje  0.831
2001 Boraud T, Bezard E, Bioulac B, Gross CE. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain : a Journal of Neurology. 124: 546-57. PMID 11222455 DOI: 10.1093/Brain/124.3.546  0.819
2001 Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease The Journal of Neuroscience. 21: 6853-6861. DOI: 10.1523/JNEUROSCI.21-17-06853.2001  0.812
2000 Bezard E, Dovero S, Imbert C, Boraud T, Gross CE. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse (New York, N.Y.). 38: 363-8. PMID 11020240 DOI: 10.1002/1098-2396(20001201)38:3<363::Aid-Syn16>3.0.Co;2-A  0.812
2000 Bezard E, Jaber M, Gonon F, Boireau A, Bloch B, Gross CE. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. The European Journal of Neuroscience. 12: 2892-900. PMID 10971632 DOI: 10.1046/j.1460-9568.2000.00180.x  0.724
2000 Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Poewe W, Wenning GK, Tison F. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 531-6. PMID 10830420 DOI: 10.1002/1531-8257(200005)15:3<531::AID-MDS1017>3.0.CO;2-C  0.466
2000 Boraud T, Bezard E, Bioulac B, Gross CE. Ratio of inhibited-to-activated pallidal neurons decreases dramatically during passive limb movement in the MPTP-treated monkey. Journal of Neurophysiology. 83: 1760-3. PMID 10712496 DOI: 10.1152/Jn.2000.83.3.1760  0.807
2000 Boraud T, Bezard E, Stutzmann JM, Bioulac B, Gross CE. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience Letters. 281: 75-8. PMID 10704746 DOI: 10.1016/S0304-3940(00)00780-1  0.834
2000 Imbert C, Bezard E, Guitraud S, Boraud T, Gross CE. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. Journal of Neuroscience Methods. 96: 71-6. PMID 10704673 DOI: 10.1016/S0165-0270(99)00184-3  0.756
1999 Bezard E, Brefel C, Tison F, Peyro-Saint-Paul H, Ladure P, Rascol O, Gross CE. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 23: 1237-46. PMID 10581645 DOI: 10.1016/S0278-5846(99)00067-6  0.683
1999 Gross CE, Boraud T, Guehl D, Bioulac B, Bezard E. From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research? Progress in Neurobiology. 59: 509-32. PMID 10515666 DOI: 10.1016/S0301-0082(99)00015-5  0.814
1999 Guehl D, Bezard E, Dovero S, Boraud T, Bioulac B, Gross C. Trichloroethylene and parkinsonism: a human and experimental observation. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 6: 609-11. PMID 10457397 DOI: 10.1046/J.1468-1331.1999.650609.X  0.819
1999 Bezard E, Boraud T, Nguyen JP, Velasco F, Keravel Y, Gross C. Cortical stimulation and epileptic seizure: a study of the potential risk in primates. Neurosurgery. 45: 346-50. PMID 10449080 DOI: 10.1097/00006123-199908000-00030  0.728
1999 Bezard E, Boraud T, Bioulac B, Gross CE. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. The European Journal of Neuroscience. 11: 2167-70. PMID 10336685 DOI: 10.1046/j.1460-9568.1999.00627.x  0.83
1999 Bezard E, Gross CE, Fournier MC, Dovero S, Bloch B, Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Experimental Neurology. 155: 268-73. PMID 10072302 DOI: 10.1006/exnr.1998.6995  0.821
1998 Bezard E, Stutzmann JM, Imbert C, Boraud T, Boireau A, Gross CE. Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model. European Journal of Pharmacology. 356: 101-4. PMID 9774238 DOI: 10.1016/S0014-2999(98)00537-8  0.795
1998 Bezard E, Imbert C, Gross CE. Experimental models of Parkinson's disease: from the static to the dynamic. Reviews in the Neurosciences. 9: 71-90. PMID 9711900 DOI: 10.1515/Revneuro.1998.9.2.71  0.732
1998 Bezard E, Bioulac B, Gross CE. Glutamatergic compensatory mechanisms in experimental parkinsonism. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 22: 609-23. PMID 9682276 DOI: 10.1016/S0278-5846(98)00030-X  0.787
1998 Bezard E, Gross CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Progress in Neurobiology. 55: 93-116. PMID 9618745 DOI: 10.1016/S0301-0082(98)00006-9  0.737
1998 Boraud T, Bezard E, Guehl D, Bioulac B, Gross C. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Research. 787: 157-60. PMID 9518590 DOI: 10.1016/S0006-8993(97)01563-1  0.812
1998 Bezard E, Boraud T, Imbert C, Dovero S, Bioulac B, Gross CE. Towards a dynamic approach of experimental parkinsonism Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22: 1317-1329. DOI: 10.1016/S0278-5846(98)00072-4  0.826
1997 Bezard E, Dovero S, Bioulac B, Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Experimental Neurology. 148: 288-92. PMID 9398471 DOI: 10.1006/exnr.1997.6648  0.824
1997 Bezard E, Imbert C, Deloire X, Bioulac B, Gross CE. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Research. 766: 107-12. PMID 9359593 DOI: 10.1016/S0006-8993(97)00531-3  0.823
1997 Bezard E, Dovero S, Bioulac B, Gross CE. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neuroscience Letters. 234: 47-50. PMID 9347943 DOI: 10.1016/S0304-3940(97)00663-0  0.83
1997 Bezard E, Boraud T, Bioulac B, Gross CE. Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience. 81: 399-404. PMID 9300430 DOI: 10.1016/S0306-4522(97)00226-1  0.841
1997 Beurrier C, Bezard E, Bioulac B, Gross C. Subthalamic stimulation elicits hemiballismus in normal monkey. Neuroreport. 8: 1625-9. PMID 9189903 DOI: 10.1097/00001756-199705060-00014  0.777
1997 Bezard E, Boraud T, Bioulac B, Gross CE. Presymptomatic revelation of experimental parkinsonism. Neuroreport. 8: 435-8. PMID 9080424 DOI: 10.1097/00001756-199701200-00012  0.841
1996 Boraud T, Bezard E, Bioulac B, Gross C. High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey. Neuroscience Letters. 215: 17-20. PMID 8880743 DOI: 10.1016/S0304-3940(96)12943-8  0.816
Show low-probability matches.